Tendinopathy - Pipeline Insight, 2022
Description
Tendinopathy - Pipeline Insight, 2022
DelveInsight’s, Tendinopathy - Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Tendinopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Tendinopathy: Overview
Tendinopathies are very common in general population and a huge number of tendon-related procedures take place annually worldwide, with significant socio-economic repercussions. Numerous treatment options are commonly used for tendon disorders. Tendon disorders are a class of pathology that includes traumatic injuries as well as chronic diseases, such as tendinopathy. They represent some of the most frequent orthopedic diagnosis, accounting for over 30% of all musculoskeletal consultations. Over 30 million human tendon-related procedures take place annually worldwide with significant socio-economic repercussions in terms of lost working hours and economic expenditure.
Numerous treatment options are proposed in the treatment of patients affected by tendinopathies. Usually, they can be grouped in pharmacological therapies, physical therapies, and therapeutic exercise.
""Tendinopathy - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tendinopathy pipeline landscape is provided which includes the disease overview and Tendinopathy treatment guidelines. The assessment part of the report embraces, in depth Tendinopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tendinopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
dHACM: MiMedx
dHACM is a micronized dehydrated Human Amnion Chorion Membrane developed by MiMedx for Tendinitis and is currently in the phase III stage of development. AmnioFix is processed using Purion, a unique patented method for placental-based allografts according to the American Association of Tissue Banks (AATB) standards. The product is derived from donated C-sections of live births in the US. The product faces active preservation of the extracellular matrix (ECM), regulatory proteins, and elimination of blood contaminants through a proprietary cleansing process. For an additional level of safety, the product is terminally sterilized.
Further product details are provided in the report……..
Tendinopathy: Therapeutic Assessment
This segment of the report provides insights about the Tendinopathy drugs segregated based on following parameters that define the scope of the report, such as:
Tendinopathy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tendinopathy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tendinopathy drugs.
Tendinopathy Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, Tendinopathy - Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Tendinopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Tendinopathy: Overview
Tendinopathies are very common in general population and a huge number of tendon-related procedures take place annually worldwide, with significant socio-economic repercussions. Numerous treatment options are commonly used for tendon disorders. Tendon disorders are a class of pathology that includes traumatic injuries as well as chronic diseases, such as tendinopathy. They represent some of the most frequent orthopedic diagnosis, accounting for over 30% of all musculoskeletal consultations. Over 30 million human tendon-related procedures take place annually worldwide with significant socio-economic repercussions in terms of lost working hours and economic expenditure.
Numerous treatment options are proposed in the treatment of patients affected by tendinopathies. Usually, they can be grouped in pharmacological therapies, physical therapies, and therapeutic exercise.
""Tendinopathy - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tendinopathy pipeline landscape is provided which includes the disease overview and Tendinopathy treatment guidelines. The assessment part of the report embraces, in depth Tendinopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tendinopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence R&D Tendinopathy. The therapies under development are focused on novel approaches to treat/improve Tendinopathy.
dHACM: MiMedx
dHACM is a micronized dehydrated Human Amnion Chorion Membrane developed by MiMedx for Tendinitis and is currently in the phase III stage of development. AmnioFix is processed using Purion, a unique patented method for placental-based allografts according to the American Association of Tissue Banks (AATB) standards. The product is derived from donated C-sections of live births in the US. The product faces active preservation of the extracellular matrix (ECM), regulatory proteins, and elimination of blood contaminants through a proprietary cleansing process. For an additional level of safety, the product is terminally sterilized.
Further product details are provided in the report……..
Tendinopathy: Therapeutic Assessment
This segment of the report provides insights about the Tendinopathy drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Tendinopathy
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Molecule Type
- Small molecule
- Cell Therapy
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Tendinopathy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tendinopathy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tendinopathy drugs.
Tendinopathy Report Insights
- Tendinopathy Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Tendinopathy drugs?
- How many Tendinopathy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Tendinopathy?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Tendinopathy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Tendinopathy and their status?
- What are the key designations that have been granted to the emerging drugs?
- MiMedx
- Hisamitsu Pharmaceuticals
- Seikagaku Corporation
- MetrioPharm
- dHACM
- Diclofenac sodium transdermal patch
- SI-613
- MP1032
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Tendinopathy: Overview
- What is Tendinopathy?
- Types of Tendinopathy
- Causes
- Epidemiology and Risk Factors
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Tendinopathy– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- dHACM: MiMedx
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- SI-613: Seikagaku Corporation
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Tendinopathy Key Companies
- Tendinopathy Key Products
- Tendinopathy- Unmet Needs
- Tendinopathy- Market Drivers and Barriers
- Tendinopathy- Future Perspectives and Conclusion
- Tendinopathy Analyst Views
- Tendinopathy Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
